Microsoft word - program translational opportunities for (6).doc


6:30-9:00: Registration

7th floor Auditorium Shriners Hospital for Children
8:45-9:00: Introduction

Session I:
Therapies for Skin Disorders (Chair: Leena Bruckner-
Jakub Tolar “Hematogenous cells for skin extracellular matrix
Leena Bruckner-Tuderman “DEB mouse: wound healing, cancer
and therapeutic perspectives”
10:00-10:15: Vitali Alexeev “Development of protein therapeutics for Junctional
10:20-10:50: Coffee Break
10:50-11:05: Tracy Adair-Kirk “Dox-controllable, keratinocyte-targeted
expression of human laminin 2 rescues laminin 2 KO mice and generates a model of junctional epidermolysis bullosa” 11:10-11:35: Jouni Uitto “Pseudoxanthoma Elasticum—the paradigm of ectopic
mineralization disorders: towards treatment and cure” 11:40-12:05: Anne De Paepe “New genes and molecular pathways in the
12:10-12:30: General Discussion
Lunch: 12:30-1:30 in the 7th floor Auditorium foyer, Play Deck, or Board Room
Session II: New Targets for Treating Fibrosis (Chair: Leena Bruckner-
Elizabeth Gerber “New treatment strategies for scleroderma
derived from mouse models of Stiff Skin Syndrome”
Dean Sheppard “TGF activation by integrins”
Diane Shelton “Fibrosis in canine muscular dystrophies and other
inherited myopathies”
Olga Igoucheva “Disease-site targeting and application of adult
stem cells for heritable skin and muscle disorders”
Gerhard Sengle “Microenvironmental regulation by fibrillin-1”
Poster Session, Wine and Cheese Reception in the Auditorium foyer
7th floor Auditorium Shriners Hospital for Children
Session III: Treating Bone Disorders (Chair: Hans Peter Bächinger)
9:00-9:25: Hans Peter Bächinger “The collagen folding machinery and
David Russell “Eliminating collagen mutations in Osteogenesis
Imperfecta stem cells”
10:00-10:15: Cathleen Raggio “Comparison of Rankl inhibition and alendronate
treatment in a growing mouse model of Osteogenesis Imperfecta” 10:20-10:50: Coffee Break
10:50-11:05: Elena Pokidysheva “The use of minoxidil, a translational inhibitor
for lysyl hydroxylases, as a drug for treatment of recessive Osteogenesis Imperfecta” 11:10-11:35: Gerard Karsenty “Serotonin regulation of bone mass”
11:40-11:55: Sherrill Adams “Type III collagen: an essential component of the
12:00-12:30: General Discussion
Lunch: 12:30-1:30 in the 7th floor Auditorium foyer, Play Deck, or Board Room
Session IV: Novel Therapeutic Approaches for the Chondrodysplasias
(Chair: William Horton)
Kazuwa Nakao “Translational science of the CNP/GC-B/cGMP
system for achondroplasia”
Bill Horton “New strategies for targeting FGFR3 in achondroplasia”
Eileen Shore “Fibrodysplasia Ossificans Progressiva—a genetic
disorder of ectopic endochondral ossification”
Linda Sandell “The cartilage collagen N-propeptide, PIIBNP,
inhibits angiogenesis and kills tumors”
Jacqueline Hecht “CHOP is essential for mutant COMP retention
and apoptosis in chondrocytes in an inducible transgenic mouse
Banquet: 6:30-9:30 at the Heathman Hotel Welcome from Carolyn Levering, CEO and President, and Josephine
, Vice President, of the National Marfan Foundation
Featured Speaker: David L. Rimoin, M.D., Ph.D., Steven Spielberg Chair
and Distinguished Professor of Pediatrics, Cedars-Sinai Medical Center,
David Geffen School of Medicine at UCLA

7th floor Auditorium Shriners Hospital for Children

Session V: Therapies for Vascular Disorders (Chair: Hal Dietz)
Hal Dietz “Found in translation: new insights regarding the
pathogenesis of Marfan syndrome and related disorders”
Fransiska Malfait “Clinical, biochemical and molecular overview of
the Ehlers-Danlos syndrome vascular type”
9:50-10:05: Julie De Backer “New therapeutic challenges in vascular EDS and
10:10-10:40: Coffee Break
10:40-10:55: Wanfen Xiong “Doxycycline attenuates TGF- activation and
aneurysm rupture through its MMP-2 inhibition in Marfan syndrome” 11:00-11:25: Francesco Ramirez “Genetic dissection of bone and vascular
11:30-12:00: General Discussion
Lunch: 12:00-1:00 in the 7th floor Auditorium foyer, Play Deck, or Board Room
Session VI: New Targets for Treating Marfan Syndrome and Related
(Chair: Lynn Sakai)
Valerie Cormier-Daire “Understanding
ADAMTS/ADAMTSL/Fibrillin functions by studying the acromelic
dysplasia group”
Dan Rifkin “Multiple functions of LTBPs in Marfan-related
phenotypes; a new challenge for therapy”
Lynn Sakai “Microfibril fragmentation and BMP signaling in Marfan
Jason Cook “Genetic dissection of vascular pathology in Marfan
Hiromi Yanagisawa “Dual role of fibulin-5 in prevention of pelvic
organ prolapse”
Alison Frand “The fibrillin-like Fbn-1 protein of C.elegans regulates
molting cycles”

7th floor Auditorium Shriners Hospital for Children

Session VII: Hot Topics (Chair: Peter Byers)
Peter Byers “Clinical and molecular heterogeneity of recessive
Osteogenesis Imperfecta”
Elena Makareeva “Chaperoning osteogenesis: new protein folding
paradigms and their implications for Osteogenesis Imperfecta”
Sergei Boudko “Structural and biophysical studies of the mutation
in cyclophilin B that causes hyperelastosis cutis in the American
Quarter Horse”
10:00-10:30 Coffee Break
Session VIII: Summary and Recommendations (Chair: Peter Byers; Co-
Chairs: Leena Bruckner-Tuderman, Hans Peter Bächinger, Bill Horton, Hal
Dietz, and Lynn Sakai
10:30-10:55: Peter Byers “New Directions: where is the compass?”
11:00-12:00: General Discussion


Microsoft word - revised 2013 prepopik split-dose.doc

Maryland Diagnostic & Therapeutic Endo Center 621 Ridgely Avenue, Suite 101 Annapolis, MD 21401 You will receive sedation and must have a family member or friend who is 18 years old or older to accompany you and drive you home. A taxi is not an approved means of transportation without a family member or friend. If you are diabetic contact the pre-op nurse at 410-224-3636 ext 496 to discus

Microsoft word - bahadori babak_publ-liste

Dr. Babak Bahadori Geb.: 25. März 1966 Publikationsliste 28. Jänner 2009 Originalarbeiten (1) Bahadori B , Uitz E, Truschnig-Wilders M, Pilger E, Renner W. Polymorphisms of the Hypoxia Inducible Factor Gene and Peripheral Arterial Disease. In progress. (2) Bahadori B , Uitz E, Thonhofer R, Trummer M, Pestemer-Lach I, MacCarty M, Krejs GJ. Omega-3 fatty acids as adj

Copyright © 2010-2019 Pdf Physician Treatment